Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$79.83 /

+0.37 (+0.47%)

, AGN

Allergan

$138.83 /

-1.38 (-0.98%)

04:55
05/21/19
05/21
04:55
05/21/19
04:55

The AASLD, AGAless than ASGE & SSAT to hold a conference

Association for Study of Liver Diseases (AASLD), American Gastroenterological Association (AGA), American Society for Gastrointestinal Endoscopy (ASGE) and Society for Surgery of the Alimentary Tract (SSAT) co-host Digestive Disease Week 2019 in San Diego, CA on May 18-21.

ABBV

AbbVie

$79.83 /

+0.37 (+0.47%)

AGN

Allergan

$138.83 /

-1.38 (-0.98%)

IRWD

Ironwood

$11.17 /

-0.08 (-0.71%)

APEN

Apollo Endosurgery

$3.60 /

-0.36 (-9.09%)

BSX

Boston Scientific

$37.31 /

-0.01 (-0.03%)

BMY

Bristol-Myers

$46.29 /

-0.55 (-1.17%)

CELG

Bought by BMY

$94.84 /

-0.61 (-0.64%)

CNMD

Conmed

$80.07 /

-0.26 (-0.32%)

DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

LLY

Eli Lilly

$116.24 /

+0.17 (+0.15%)

EXAS

Exact Sciences

$96.03 /

-0.14 (-0.15%)

SGYP

Synergy Pharmaceuticals

$0.00 /

+ (+0.00%)

PFE

Pfizer

$41.58 /

+0.12 (+0.29%)

PEP

PepsiCo

$129.98 /

-0.54 (-0.41%)

MRK

Merck

$78.86 /

+0.15 (+0.19%)

MDT

Medtronic

$87.55 /

-0.19 (-0.22%)

IDXG

Interpace Biosciences

$0.69 /

-0.0136 (-1.94%)

WTKWY

Wolters Kluwer

$0.00 /

+ (+0.00%)

TKPYY

Use TAK

$0.00 /

+ (+0.00%)

SHPG

Acquired by TAK

$0.00 /

+ (+0.00%)

GILD

Gilead

$65.85 /

-0.49 (-0.74%)

GSK

GlaxoSmithKline

$39.40 /

-0.065 (-0.16%)

ICPT

Intercept

$84.91 /

-1.52 (-1.76%)

  • 21

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 23

    May

  • 28

    May

  • 28

    May

  • 29

    May

  • 29

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 06

    Jun

  • 17

    Jun

  • 18

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 26

    Jun

  • 27

    Jun

  • 09

    Jul

  • 16

    Jul

  • 30

    Jul

  • 30

    Jul

  • 06

    Aug

  • 03

    Sep

  • 20

    Sep

  • 04

    Nov

  • 13

    Nov

ABBV AbbVie
$79.83 /

+0.37 (+0.47%)

05/14/19 Barclays
Myovant Sciences selloff overdone after report of relugolix data, says Barclays
04/28/19 BMO Capital
AbbVie upgraded to Market Perform from Underperform at BMO Capital
04/11/19 Evercore ISI
Myovant Sciences initiated with an Outperform at Evercore ISI
03/26/19 William Blair
William Blair upgrades Vertex to Outperform after 'subpar' competitor data
AGN Allergan
$138.83 /

-1.38 (-0.98%)

05/17/19 Lake Street
Allergan ruling removes overhang on Harrow Health, says Lake Street
05/10/19 SunTrust
Allergan price target lowered to $170 from $178 at SunTrust
05/08/19 RBC Capital
Allergan price target lowered to $140 from $165 at RBC Capital
05/01/19 Wells Fargo
Wells hopes Allergan shareholder vote marks end of 'distractive narrative'
IRWD Ironwood
$11.17 /

-0.08 (-0.71%)

03/27/19 Morgan Stanley
Morgan Stanley upgrades Ironwood to Equal Weight on more stable Linzess growth
03/27/19 Morgan Stanley
Ironwood upgraded to Equal Weight from Underweight at Morgan Stanley
02/26/19 Spin-Off Research
Ironwood initiated with a Buy at Spin-Off Research
02/25/19 H.C. Wainwright
Ironwood upgraded to Neutral from Sell at H.C. Wainwright
APEN Apollo Endosurgery
$3.60 /

-0.36 (-9.09%)

03/18/19 Piper Sandler
Piper says Apollo's OverStitch growth more important than balloon sales declines
01/02/19 Northland
Apollo Endosurgery upgraded to Market Perform from Underperform at Northland
12/18/18 Craig-Hallum
Craig-Hallum says Apollo's divestiture makes it more attractive takever target
12/18/18 Piper Sandler
Apollo Endosurgery target lowered to $5.50 from $7 at Piper Jaffray
BSX Boston Scientific
$37.31 /

-0.01 (-0.03%)

05/13/19
Boston Scientific upgraded to Outperform at Evercore ISI on revenue growth
05/13/19 Evercore ISI
Boston Scientific upgraded to Outperform from In Line at Evercore ISI
04/23/19 Piper Sandler
Boston Scientific Lotus approval may accelerate share gains, says Piper Jaffray
04/16/19 Wells Fargo
Boston Scientific mesh sales impacted by FDA recall about $25M, says Wells Fargo
BMY Bristol-Myers
$46.29 /

-0.55 (-1.17%)

05/20/19
Bristol-Myers downgraded to Hold from Buy at Argus
05/20/19 Argus
Bristol-Myers downgraded to Hold from Buy at Argus
05/03/19 JPMorgan
Bristol-Myers reinstated with an Overweight at JPMorgan
05/03/19 Barclays
Celgene downgraded to Equal Weight from Overweight at Barclays
CELG Bought by BMY
$94.84 /

-0.61 (-0.64%)

05/07/19 Piper Sandler
Sutro regaining U.S. rights from Celgene a 'clear positive,' says Piper Jaffray
CNMD Conmed
$80.07 /

-0.26 (-0.32%)

04/18/19
Fly Intel: Top five analyst initiations
04/17/19 Stifel
Conmed initiated with a Buy at Stifel
04/16/19 Needham
Conmed price target raised to $94 from $87 at Needham
02/27/19 Needham
Conmed price target raised to $87 from $79 at Needham
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$116.24 /

+0.17 (+0.15%)

04/24/19
Fly Intel: Top five analyst upgrades
04/23/19 Edward Jones
Eli Lilly upgraded to Buy from Hold at Edward Jones
04/22/19 BMO Capital
Eli Lilly price target lowered to $130 from $134 at BMO Capital
04/18/19 Piper Sandler
Teva gains ground on Amgen in latest migraine survey, says Piper Jaffray
EXAS Exact Sciences
$96.03 /

-0.14 (-0.15%)

05/01/19 Craig-Hallum
Exact Sciences price target raised to $115 from $95 at Craig-Hallum
05/01/19 Jefferies
Exact Sciences price target raised to $115 from $100 at Jefferies
05/01/19 Canaccord
Exact Sciences price target raised to $110 from $100 at Canaccord
05/01/19 BTIG
Exact Sciences price target raised to $130 from $110 at BTIG
SGYP Synergy Pharmaceuticals
$0.00 /

+ (+0.00%)

12/12/18 Wells Fargo
Bausch purchase of Synergy an 'inconsequential financial deal,' says Wells Fargo
12/12/18 Stifel
Synergy's GI assets 'fit squarely' into Bausch Health GI wheelhouse, says Stifel
10/26/18 Canaccord
Synergy Pharmaceuticals downgraded to Hold at Canaccord
10/26/18 BTIG
Synergy Pharmaceuticals downgraded to Neutral from Buy at BTIG
PFE Pfizer
$41.58 /

+0.12 (+0.29%)

05/14/19
Solid Biosciences downgraded to Underperform at Credit Suisse
05/13/19 Wells Fargo
Lawsuit against Teva, others to hit generic drug stocks, says Wells Fargo
05/09/19 Baird
Baird names Sarepta a 'Fresh Pick' ahead of Pfizer data
05/07/19 Roth Capital
Eidos Therapeutics raised to $51 from $28 at Roth Capital
PEP PepsiCo
$129.98 /

-0.54 (-0.41%)

05/14/19 Wells Fargo
PepsiCo price target raised to $127 from $120 at Wells Fargo
04/18/19
Fly Intel: Top five analyst upgrades
04/18/19 SunTrust
PepsiCo price target raised to $120 from $110 at SunTrust
04/18/19 Argus
PepsiCo price target raised to $146 from $128 at Argus
MRK Merck
$78.86 /

+0.15 (+0.19%)

05/16/19 Jefferies
Jefferies calls Iovance 'big winner' at ASCO, sees up to 40% share rally
05/14/19 H.C. Wainwright
BioLineRx has multiple catalysts coming in 2019, says H.C. Wainwright
05/13/19
Fly Intel: Top five analyst upgrades
05/13/19 Atlantic Equities
Merck upgraded to Overweight from Neutral at Atlantic Equities
MDT Medtronic
$87.55 /

-0.19 (-0.22%)

05/10/19 SunTrust
Axonics price target raised to $33 from $26 at SunTrust
04/09/19 Stephens
Medtronic outcomes-based program could be headwind for DexCom, says Stephens
03/29/19 Stifel
IntriCon added to Select List at Stifel
03/18/19 Wells Fargo
Edwards Lifesciences price target raised to $202 from $188 at Wells Fargo
IDXG Interpace Biosciences
$0.69 /

-0.0136 (-1.94%)

06/22/18
On The Fly: Top five analyst initiations
06/22/18 Ladenburg
Interpace Diagnostics initiated with a Buy at Ladenburg
WTKWY Wolters Kluwer
$0.00 /

+ (+0.00%)

05/17/19 JPMorgan
Wolters Kluwer downgraded to Underweight from Neutral at JPMorgan
TKPYY Use TAK
$0.00 /

+ (+0.00%)

05/09/19 Stifel
Novartis deal makes Aerie 'look like a steal' at current levels, says Stifel
12/20/18 William Blair
Shire downgraded to Market Perform from Outperform at William Blair
12/12/18 SunTrust
Shire downgraded to Hold at SunTrust on Takeda merger
11/06/18 SunTrust
Shire price target lowered to $190 from $205 at SunTrust
SHPG Acquired by TAK
$0.00 /

+ (+0.00%)

12/18/18 RBC Capital
AMD addition to Nasdaq-100 a 'small near-term positive', says RBC Capital
12/17/18 Piper Sandler
Shire approval another potential headwind for Allergan, says Piper Jaffray
GILD Gilead
$65.85 /

-0.49 (-0.74%)

05/20/19 Credit Suisse
Gilead initiated with a Neutral at Credit Suisse
05/13/19 Jefferies
Gilead shares reflect 'undue bearish outlook,' says Jefferies
05/10/19 B. Riley FBR
Intercept added to Alpha Generator list at B. Riley FBR
05/03/19 Wells Fargo
Intercept upgraded to Outperform following survey of doctors at Wells Fargo
GSK GlaxoSmithKline
$39.40 /

-0.065 (-0.16%)

02/22/19 UBS
GlaxoSmithKline downgraded to Neutral from Buy at UBS
02/01/19 Wells Fargo
Perrigo's ProAir opportunity 'may be vaporizing,' says Wells Fargo
01/31/19 Wells Fargo
FDA approval of Mylan's Advair 'overdue,' says Wells Fargo
ICPT Intercept
$84.91 /

-1.52 (-1.76%)

05/14/19 Citi
CymaBay initiated with a Buy at Citi
05/13/19 Wedbush
Intercept price target lowered to $243 from $251 at Wedbush

TODAY'S FREE FLY STORIES

Conference/Events
The ASTCT and CIBMTR to hold a joint meeting » 04:55
02/22/20
02/22
04:55
02/22/20
04:55
ABBV

AbbVie

$94.96 /

+0.7 (+0.74%)

, ADPT

Adaptive Biotechnologies

$34.19 /

+0.37 (+1.09%)

, AMGN

Amgen

$222.80 /

+0.62 (+0.28%)

, ATNM

Actinium Pharmaceuticals

$0.26 /

+0.0088 (+3.50%)

, ATRA

Atara Biotherapeutics

$13.18 /

-0.34 (-2.51%)

, AZN

AstraZeneca

$50.17 /

+1.2 (+2.45%)

, BLUE

Bluebird Bio

$80.15 /

-2.38 (-2.88%)

, CDNA

CareDx

$28.25 /

+0.13 (+0.46%)

, CDTX

Cidara Therapeutics

$3.16 /

+ (+0.00%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.48 /

+0.38 (+7.45%)

, GMDA

Gamida Cell

$4.55 /

-0.2 (-4.21%)

, GSK

GlaxoSmithKline

$43.11 /

+0.35 (+0.82%)

, HUM

Humana

$369.65 /

-1.9 (-0.51%)

, INCY

Incyte

$80.89 /

-1.88 (-2.27%)

, JAZ

Jazz Technologies

$0.00 /

+ (+0.00%)

, KDMN

Kadmon

$5.08 /

+0.03 (+0.59%)

, MGTA

Magenta Therapeutics

$14.00 /

-0.02 (-0.14%)

, MRK

Merck

$82.34 /

-0.14 (-0.17%)

, NVS

Novartis

$96.75 /

+0.44 (+0.46%)

, PFE

Pfizer

$35.71 /

-0.13 (-0.36%)

, RCKT

Rocket Pharmaceuticals

$22.73 /

-1.01 (-4.25%)

, SGEN

Seattle Genetics

$117.00 /

-1.3 (-1.10%)

, SNY

Sanofi

$50.83 /

+0.07 (+0.14%)

, TAK

Takeda Pharmaceutical

$18.78 /

+0.195 (+1.05%)

American Society for…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
eBay says Payments expected to generate $2B of revenue by 2022 » 18:42
02/21/20
02/21
18:42
02/21/20
18:42
EBAY

eBay

$38.19 /

+0.51 (+1.35%)

In addition to…

In addition to eBay's portfolio review, the company's management team has executed numerous value creating actions since the beginning of 2019 that are transforming eBay's business and strengthening its foundation for growth. Among others, these actions include: Scaled Managed Payments in the U.S. and Germany; by 2022, Payments is expected to generate $2B of revenue and $0.5B of operating income; Delivered a point of margin improvement and committed to at least 2 additional points of margin expansion by 2022 while investing in revenue growth initiatives; Executed $5B in share buybacks and recently announced expansion of 2020 share buyback plan from $1.5B to $4.5B; Implemented eBay's first ever dividend and committed to a 14% increase in 2020; Increased focus on Marketplace volume growth with a reorganization of the executive leadership team and a re-prioritized customer-focused plan that includes improved vertical buyer experiences, more data & tools for sellers, and increased platform conversion leveraging an expanded structured data foundation. eBay's Board and management team are confident that the above actions will help achieve the previously stated priorities for 2020 and position eBay for sustainable, profitable long-term growth.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
eBay says in 'active discussions with multiple parties' for sale of Classifieds » 18:39
02/21/20
02/21
18:39
02/21/20
18:39
EBAY

eBay

$38.19 /

+0.51 (+1.35%)

eBay issued the following…

eBay issued the following statement regarding the previously announced strategic review of eBay's Classifieds Group: "eBay has been exploring potential value-creating alternatives for Classifieds and continues to be in active discussions with multiple parties regarding a potential transaction. As previously noted, eBay expects to provide an update regarding this process by the middle of the year. eBay remains committed to maximizing the value of Classifieds for eBay shareholders. eBay's Board and management are committed to driving significant returns to shareholders by maximizing the value of Classifieds and positioning our Marketplace business for long-term success," said Scott Schenkel, interim CEO of eBay. "The Classifieds review process, together with the StubHub sale and our initiatives to increase volume, revenues, margins, and cash flow while continuing to invest in long-term profitable growth, demonstrate this commitment. We are acting with urgency while focusing on the ultimate objective of maximizing the value of Classifieds."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Italy reports first coronavirus-related death, Bloomberg says » 17:47
02/21/20
02/21
17:47
02/21/20
17:47
SPX

S&P 500

$0.00 /

+ (+0.00%)

, SPY

SPDR S&P 500 ETF Trust

$333.48 /

-3.49 (-1.04%)

Bloombereg cites…

Bloombereg cites Corriere.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Citi sees 'reasonably possible' legal costs of up to $1.3B in aggregate » 17:46
02/21/20
02/21
17:46
02/21/20
17:46
C

Citi

$76.45 /

-1.76 (-2.25%)

According to a regulatory…

According to a regulatory filing, Citi estimated that the reasonably possible unaccrued loss for various legal matters ranges up to roughly $1.3B in the aggregate. For some of the matters included within this estimation, an accrual has been made because a loss is believed to be both probable and reasonably estimable, but an exposure to loss exists in excess of the amount accrued. In these cases, the estimate reflects the reasonably possible range of loss in excess of the accrued amount. For other matters included within this estimation, no accrual has been made because a loss, although estimable, is believed to be reasonably possible, but not probable; in these cases, the estimate reflects the reasonably possible loss or range of loss. As of December 31, 2019, Citigroup estimates that the reasonably possible unaccrued loss for these matters ranges up to approximately $1.3B in the aggregate. These estimates are based on currently available information. As available information changes, the matters for which Citigroup is able to estimate will change, and the estimates themselves will change. In addition, while many estimates presented in financial statements and other financial disclosures involve significant judgment and may be subject to significant uncertainty, estimates of the range of reasonably possible loss arising from litigation and regulatory proceedings are subject to particular uncertainties.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
WarnerMedia's HBO Max to include reunion special of 'Friends,' WSJ reports » 17:41
02/21/20
02/21
17:41
02/21/20
17:41
T

AT&T

$38.54 /

-0.075 (-0.19%)

WarnerMedia's HBO…

WarnerMedia's HBO Max service will include a special reunion of the television series "Friends" as well as all of the show's previous episodes when the streaming service rolls out in May, the Wall Street Journal's Allison Prang and Joe Flint report. The company said that all six of the main stars of "Friends" will be part of the reunion special, the authors say. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
FleetCor's Johnson sells 15,000 common shares » 17:35
02/21/20
02/21
17:35
02/21/20
17:35
FLT

FleetCor

$308.94 /

-8.45 (-2.66%)

In a regulatory filing,…

In a regulatory filing, FleetCor Technologies director Mark A. Johnson disclosed the sale of 15,000 common shares of the company at a price of $321.333 per share on February 19.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Amazon wants internal DOD documents in JEDI cloud case, Bloomberg reports » 17:31
02/21/20
02/21
17:31
02/21/20
17:31
AMZN

Amazon.com

$2,094.29 /

-58.64 (-2.72%)

, MSFT

Microsoft

$178.46 /

-5.9 (-3.20%)

Amazon (AMZN) has asked a…

Amazon (AMZN) has asked a court to force the U.S. government to provide documents related to Defense Secretary Mark Esper's decision to recuse himself from making decisions on the $10B JEDI cloud contract that the Pentagon awarded to Microsoft (MSFT) in December, Bloomberg's Naomi Nix reports. According to a court filing, Amazon is eyeing a trove of documents to strengthen its challenge of the Pentagon's JEDI cloud contract, Nix says. Amazon has claimed that U.S. President Donald Trump's meddling in the matter cost the ecommerce giant the contract, Nix notes. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Idexx Laboratories director sells 39.1K shares of common stock » 17:29
02/21/20
02/21
17:29
02/21/20
17:29
IDXX

Idexx Laboratories

$278.55 /

-2.92 (-1.04%)

In a regulatory filing,…

In a regulatory filing, Idexx Laboratories disclosed that its director Jonathan Ayers sold 39.1K shares of common stock on February 19th. The total transaction size was about $11.5M.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Jernigan Capital cuts quarterly dividend to 23c from 35c per share » 17:24
02/21/20
02/21
17:24
02/21/20
17:24
JCAP

Jernigan Capital

$20.30 /

+0.07 (+0.35%)

The dividend is payable…

The dividend is payable on April 15, 2020 to stockholders of record on April 1, 2020.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Synthesis Energy Systems discloses additional Nasdaq delinquency notice » 17:23
02/21/20
02/21
17:23
02/21/20
17:23
SES

Synthesis Energy Systems

$5.49 /

+ (+0.00%)

Synthesis Energy Systems…

Synthesis Energy Systems announced that the company received an additional staff determination delinquency notification letter from the The Nasdaq Stock Market LLC due to the company's non-compliance with Nasdaq Listing Rule 5250(c)(1), as a result of the company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2019. The company is required to present its views with respect to this additional deficiency to the Panel in writing no later than February 27, 2020 under Listing Rule 5810(d). Robert Rigdon, the company's CEO, commented: "The company is progressing its important merger transaction with AFE and acquisition of additional ownership in Batchfire Resources. We believe these transactions, now underway, have the potential to bring growth and value to the company's shareholders and debenture holders. The late filing of our Form 10-Q for the quarter ended December 31, 2019 is the result delays related to derivative accounting protocol and value analysis regarding the merger-related debt restructuring undertaken by the company in October 2019. We are actively working with our auditors and our advisors to complete the work in the most expeditious manner possible."

Syndicate
Pebblebrook Hotel files automatic mixed securities shelf  17:23
02/21/20
02/21
17:23
02/21/20
17:23
PEB

Pebblebrook Hotel

$24.90 /

+0.3 (+1.22%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Phillips 66 awarded $795.34M Defense Logistics Agency contract » 17:20
02/21/20
02/21
17:20
02/21/20
17:20
PSX

Phillips 66

$89.22 /

-1.015 (-1.12%)

Phillips 66 has been…

Phillips 66 has been awarded a $795.34M fixed-price with economic-price-adjustment, indefinite-delivery/indefinite-quantity contract under solicitation for various types of fuel. These were competitive acquisitions with 32 offers received. These are one-year contracts with a 30-day carryover. Work has an April 30, 2021, performance completion date. Using customer is Defense Logistics Agency Energy. Type of appropriation is FY20 defense working capital funds. The contracting activity is the Defense Logistics Agency Energy.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Lockheed Martin awarded $233.04M Navy contract action » 17:16
02/21/20
02/21
17:16
02/21/20
17:16
LMT

Lockheed Martin

$427.29 /

+1.345 (+0.32%)

Lockheed Martin was…

Lockheed Martin was awarded a $233.04M firm-fixed-price undefinitized contract action for the procurement of Mk 41 Vertical Launching System vertical launcher module assemblies, modernization kits and spare components. This contract combines purchases for the Navy and the governments of Korea, Finland and Germany under the Foreign Military Sales program. Work is expected to be completed by March 2025. FY18, FY19 and FY20 shipbuilding and conversion, and foreign military sales funding in the amount of $46.61M was obligated at time of award and will not expire at the end of the current fiscal year. This contract was competitively procured via the Federal Business Opportunities website, with one offer received. The Naval Sea Systems Command is the contracting activity.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Xilinx recommends rejection of TRC Capital's "mini-tender" offer » 17:04
02/21/20
02/21
17:04
02/21/20
17:04
XLNX

Xilinx

$87.74 /

-2.09 (-2.33%)

Xilinx announced that it…

Xilinx announced that it has been notified of an unsolicited "mini-tender" offer by TRC Capital to purchase up to 1.5M shares of its common stock (approximately 0.6% of outstanding shares) at $81.75 per share. The offer price is approximately 4.52% below the $85.62 per share price that Xilinx common stock closed at on February 7, 2020 - the last trading day prior to the date when TRC Capital commenced its mini-tender offer - and is approximately 8.95% below the $89.79 per share at which Xilinx common stock closed on February 20, the day prior to this release. Xilinx does not endorse TRC Capital's unsolicited offer and recommends that Xilinx stockholders reject the offer and not tender their shares in response to it. Not only is the mini-tender offer at a price below the market price for Xilinx shares, as of today's date, it is also subject to numerous conditions, including TRC Capital's ability to obtain financing. Xilinx is not associated in any way with TRC Capital, its mini-tender offer or the offer documentation, nor did Xilinx have advance notice of this mini-tender offer.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Trip.com reschedules Q4 results announcement due to coronavirus » 17:03
02/21/20
02/21
17:03
02/21/20
17:03
TCOM

Trip.com Group

$33.06 /

-0.8 (-2.36%)

Trip.com Group Limited…

Trip.com Group Limited announced that it has rescheduled the announcement date for its financial results for the fourth quarter and full year 2019 to after the U.S. market closes on March 18, 2020. Trip.com Group rescheduled the announcement date of its fourth quarter and full year 2019 financial results due to the evolving situation brought on by the novel coronavirus outbreak in China. The revised date would give the company more time to observe business condition and provide visibility for the first quarter of 2020. Trip.com Group's management will hold an earnings conference call at 8:00 PM on March 18, 2020, U.S. Eastern Time.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Syndicate
InVivo Therapeutics files to sell common stock, warrants, no amount given » 17:02
02/21/20
02/21
17:02
02/21/20
17:02
NVIV

InVivo Therapeutics

$6.92 /

-0.1 (-1.42%)

H.C. Wainwright & Co.…

H.C. Wainwright & Co. is acting as exclusive placement agent in connection with this offering.

Periodicals
Google settles with state AGs over consultants in antitrust inquiry, CNBC says » 17:01
02/21/20
02/21
17:01
02/21/20
17:01
GOOG

Alphabet

$1,484.27 /

-33.78 (-2.23%)

, GOOGL

Alphabet Class A

$1,482.84 /

-33.7 (-2.22%)

Google has reached a…

Google has reached a settlement agreement with state attorneys general over outside consultants hired to work on the states' antitrust probe, CNBC's Ylan Mui and Lauren Feiner report. The settlement, which would allow consultants to continue advising the states' probe but also impose certain confidentiality restrictions, means that possible roadblocks to the investigation may be cleared for the time being, allowing the attorneys general to continue looking into the search giant's business, the authors say. A delay to the probe could hinder the states' ability to uncover important data about Google's competitive practices, the authors note. Texas is leading the investigation into the company's digital advertising operations, which is backed by 49 other attorneys general from U.S. states and territories, the authors note. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Syndicate
Uranium Energy files $100M mixed securities shelf  17:01
02/21/20
02/21
17:01
02/21/20
17:01
UEC

Uranium Energy

$0.83 /

-0.0454 (-5.19%)

 
Periodicals
Amazon wants internal DOD documents in JEDI cloud case, Bloomberg reports » 16:55
02/21/20
02/21
16:55
02/21/20
16:55
AMZN

Amazon.com

$2,094.29 /

-58.64 (-2.72%)

, MSFT

Microsoft

$178.46 /

-5.9 (-3.20%)

Amazon (AMZN) has asked a…

Amazon (AMZN) has asked a court to force the U.S. government to provide documents related to Defense Secretary Mark Esper's decision to recuse himself from making decisions on the $10B JEDI cloud contract that the Pentagon awarded to Microsoft (MSFT) in December, Bloomberg's Naomi Nix reports.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
NeuBase Therapeutics receives noncompliance letter from Nasdaq » 16:53
02/21/20
02/21
16:53
02/21/20
16:53
NBSE

NeuBase Therapeutics

$7.56 /

+0.55 (+7.85%)

NeuBase Therapeutics…

NeuBase Therapeutics announced that it received a standard notification letter from Nasdaq stating that, as a result of not having timely filed its quarterly report on Form 10-Q for the period ended December 31, 2019, NeuBase is not in compliance with Nasdaq Listing Rule 5250, which requires timely filing of periodic financial reports with the Securities and Exchange Commission. This notice has no immediate effect on the listing of NeuBase's common stock. Under Nasdaq's listing rules, NeuBase has 60 calendar days from the date of the notice to submit a plan to regain compliance. If the plan is accepted by Nasdaq, NeuBase can be granted up to 180 calendar days from the Form 10-Q's due date to regain compliance. NeuBase expects to file its Form 10-Q within the timeline prescribed by Nasdaq. In addition, NeuBase announced that it has engaged Marcum as its independent registered public accounting firm, effective February 20. The company is working diligently and expects to file its Form 10-Q for the period ended December 31, 2019 by the end of March.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
NBCUniversal in discussions to buy Vudu from Walmart, WSJ reports » 16:48
02/21/20
02/21
16:48
02/21/20
16:48
CMCSA

Comcast

$45.81 /

-0.21 (-0.46%)

, CMCSK

Comcast

$0.00 /

+ (+0.00%)

, WMT

Walmart

$118.58 /

+0.86 (+0.73%)

Comcast's (CMCSA)…

Comcast's (CMCSA) NBCUniversal is in advanced discussions to purchase video-streaming service Vudu from Walmart (WMT), the Wall Street Journal's Lillian Rizzo and Patience Haggin report, citing people familiar with the matter. Vudu, which Walmart acquired in 2010 for over $100M, allows users to buy or rent movies or shows, the authors note. The financial terms the parties are discussing could not be learned, and the talks may not lead to a deal, the authors say. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
BlackRock CFO sells 4,000 common shares » 16:42
02/21/20
02/21
16:42
02/21/20
16:42
BLK

BlackRock

$557.46 /

-9.5 (-1.68%)

In a regulatory filing,…

In a regulatory filing, BlackRock CFO and senior managing director Gary Shedlin disclosed the sale of 4,000 common shares of the company at a price of $571.4851 per share.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Esperion announces FDA approval of NEXLETOL tablet » 16:39
02/21/20
02/21
16:39
02/21/20
16:39
ESPR

Esperion

$61.77 /

-6.51 (-9.53%)

Esperion announced that…

Esperion announced that the U.S. FDA approved NEXLETOL tablet, an oral, once-daily, non-statin LDL-Cholesterol lowering medicine. NEXLETOL is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The effect of NEXLETOL on cardiovascular morbidity and mortality has not been determined. NEXLETOL is the first oral, once-daily, non-statin LDL-C lowering medicine approved since 2002 for indicated patients. NEXLETOL is a first-in-class ATP Citrate Lyase inhibitor that lowers LDL-C by inhibition of cholesterol synthesis in the liver.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Cemtrex discloses 500% increase in new orders for VR/AR development » 16:32
02/21/20
02/21
16:32
02/21/20
16:32
CETX

Cemtrex

$1.40 /

-0.06 (-4.11%)

Cemtrex announced that…

Cemtrex announced that it has received over $300,000 in new orders for the development of virtual reality, or VR, and augmented reality, or AR, applications, representing a 500% increase in the current quarter to date from the prior year. The orders were from 3 different customers and the company expects to execute these orders over the next five months. The company expects to close an additional $300,000 in new orders for virtual and augmented reality application development in the current quarter with multiple new customers based on the current sales pipeline for a total of $600,000 in FY Q2. The expected $600,000 in orders represents a 1000% percent increase in orders for VR and AR app development services compared to the same period a year ago. The company anticipates that demand for VR and AR app development services will continue to increase in the coming quarters and will be a key source of growth for the company.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.